Ventrus Biosciences (VTUS) 1.08 $VTUS
5 Stocks Poised for Breakouts
at The Street - Fri Apr 11, 7:23AM CDT
These stocks look ready to break out and trade higher from current levels.
Ventrus Biosciences Receives Date for Type B Pre-NDA Meeting With FDA for DOLIZEM (Diltiazem Hydrochloride Cream) in Anal Fissures
GlobeNewswire - Fri Apr 04, 7:17AM CDT
Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that, in response to a request from the company, the U.S. Food and Drug Administration (FDA) has scheduled a Type B pre-NDA meeting on Thursday, June 19, 2014 at which the company will seek guidance on its planned new drug application (NDA) for DOLIZEM (diltiazem hydrochloride cream) in anal fissures. Ventrus would expect to file an NDA in the second half of 2014 with an anticipated PDUFA date in the second half of 2015 if there is a positive outcome of this pre-NDA meeting.
Nasdaq stocks posting largest volume increases
AP - Wed Feb 12, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Wed Feb 12, 12:33PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Ventrus Biosciences Announces Results From Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients With Anal Fissure
GlobeNewswire - Wed Feb 12, 7:00AM CST
-- VEN 307 efficacy as expected; placebo effect greater than anticipated, resulting in no significant difference between treatments
3 Biotech Stocks Under $10 Making Big Moves
at The Street - Wed Feb 05, 8:03AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Ventrus Biosciences (VTUS) Jumps: Stock Rises 10.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 8:46AM CST
Ventrus Biosciences was a big mover last session, with shares rising nearly 11%.
Ventrus Biosciences (VTUS) Jumps: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 27, 7:39AM CST
Ventrus Biosciences Inc. was a big mover last session, as its shares rose around 7% on the day.
Global Anal Fissure Clinical Trials Review - H2 2013 Report
M2 - Tue Dec 10, 10:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/ww5g4g/anal_fissure) has announced the addition of the "Anal Fissure Global Clinical Trials Review, H2, 2013" report to their offering. Anal Fissure Global Clinical Trials Review, H2, 2013" provides data on the Anal Fissure clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anal Fissure. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anal Fissure. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Anal Fissure Therapeutics Clinical Trials - S.L.A. Pharma AG - Ventrus Biosciences, Inc. - Troikaa Pharmaceuticals Ltd. - SOFAR SPA - Ipsen S.A. - Dizney Display Company - Aptalis Pharma Inc. - Allergan, Inc. - Abbott Laboratories Clinical Trial Overview of Top Institutes / Government - Bushehr University of Medical Sciences - Birjand University of Medical Sciences - Institute of Child and Mother Health - Mazandaran University of Medical Sciences - SB Istanbul Education and Research Hospital - Rikshospitalet University Hospital - Ankara University - Huazhong University of Science & Technology - Universita degli Studi di Palermo - Hospital Universitario Reina Sofia For more information visit http://www.researchandmarkets.com/research/ww...al_fissure
Pipeline Progress at Ventrus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 29, 3:00PM CST
Ventrus completed patient enrollment and randomization of a phase III study on VEN 307.
Ventrus Biosciences Inc concludes enrolment in the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream in anal fissure patients
M2 - Tue Nov 26, 6:42AM CST
Pharmaceutical company Ventrus Biosciences Inc (NasdaqCM:VTUS) reported on Monday the completion of patient admission in the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related to anal fissure (AF), a tear in the lining of the anal canal characterised by severe anal pain associated with or after bowel movements.
Ventrus Biosciences Completes Enrollment of Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients With Anal Fissure
GlobeNewswire - Mon Nov 25, 6:30AM CST
Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced that it has completed patient enrollment and randomization in the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related to anal fissure (AF). Ventrus anticipates that data from this Phase 3 study will be available in the first quarter of 2014, and it expects to file a New Drug Application (NDA) for VEN 307 in the second quarter of 2014.
Positive Results on Ventrus' Candidate, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 12, 3:10PM CDT
Ventrus announced positive results from its two clinical dermal safety studies and one pharmacokinetic study on VEN 307.
Ventrus climbs on anal fissure drug studies
AP - Wed Sep 11, 10:46AM CDT
NEW YORK (AP) — Shares of Ventrus Biosciences jumped Wednesday after the company reported positive clinical trial results for a drug designed to treat anal fissure.
SmallCapReview.com - Small Caps On The Move - VTUS, HNR
M2 - Wed Sep 11, 10:15AM CDT
Ventrus Biosciences (Nasdaq: VTUS). Trading at $3.49, Up $0.91. Today announced positive results from two clinical dermal safety studies and one pharmacokinetic (PK) study of diltiazem hydrochloride 2% cream (VEN 307). All three studies were conducted to support the Company's planned New Drug Application (NDA) for VEN 307 as a treatment for anal fissures (AF).
Ventrus Biosciences Announces Positive Results From Clinical Dermal Safety and Pharmacokinetic Studies of Diltiazem (VEN 307)
GlobeNewswire - Wed Sep 11, 7:00AM CDT
Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced positive results from two clinical dermal safety studies and one pharmacokinetic (PK) study of diltiazem hydrochloride 2% cream (VEN 307). All three studies were conducted to support the Company's planned New Drug Application (NDA) for VEN 307 as a treatment for anal fissures (AF).
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Ventrus Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadline -- VTUS
GlobeNewswire - Sun Jul 07, 9:23AM CDT
Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Ventrus Biosciences, Inc. ("Ventrus" or the "Company"
(Nasdaq:VTUS) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 13 CIV 3429, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Ventrus between December 17, 2010 and July 25, 2012, both dates inclusive (the "Class Period" . This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Ventrus Biosciences, Inc. to Contact the Firm
GlobeNewswire - Wed Jul 03, 7:37PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of Ventrus Biosciences, Inc. ("Ventrus" or the "Company" (Nasdaq:VTUS) of the Monday, July 8, 2013 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain executives.
VENTRUS BIOSCIENCES ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Ventrus Biosciences, Inc. of Class Action Lawsuit and the Deadline of July 8, 2013 to Seek a Lead Plaintiff Position
PR Newswire - Tue Jul 02, 12:36PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Ventrus Biosciences, Inc. ("Ventrus" or the "Company" (NasdaqCM: VTUS) stock between December 17, 2010 and June 25, 2012 (the "Class Period" .
5 Stocks Poised for Breakouts
at The Street - Fri Apr 11, 7:23AM CDT
These stocks look ready to break out and trade higher from current levels.
Ventrus Biosciences Receives Date for Type B Pre-NDA Meeting With FDA for DOLIZEM (Diltiazem Hydrochloride Cream) in Anal Fissures
GlobeNewswire - Fri Apr 04, 7:17AM CDT
Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that, in response to a request from the company, the U.S. Food and Drug Administration (FDA) has scheduled a Type B pre-NDA meeting on Thursday, June 19, 2014 at which the company will seek guidance on its planned new drug application (NDA) for DOLIZEM (diltiazem hydrochloride cream) in anal fissures. Ventrus would expect to file an NDA in the second half of 2014 with an anticipated PDUFA date in the second half of 2015 if there is a positive outcome of this pre-NDA meeting.
Nasdaq stocks posting largest volume increases
AP - Wed Feb 12, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Wed Feb 12, 12:33PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Ventrus Biosciences Announces Results From Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients With Anal Fissure
GlobeNewswire - Wed Feb 12, 7:00AM CST
-- VEN 307 efficacy as expected; placebo effect greater than anticipated, resulting in no significant difference between treatments
3 Biotech Stocks Under $10 Making Big Moves
at The Street - Wed Feb 05, 8:03AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Ventrus Biosciences (VTUS) Jumps: Stock Rises 10.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 8:46AM CST
Ventrus Biosciences was a big mover last session, with shares rising nearly 11%.
Ventrus Biosciences (VTUS) Jumps: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 27, 7:39AM CST
Ventrus Biosciences Inc. was a big mover last session, as its shares rose around 7% on the day.
Global Anal Fissure Clinical Trials Review - H2 2013 Report
M2 - Tue Dec 10, 10:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/ww5g4g/anal_fissure) has announced the addition of the "Anal Fissure Global Clinical Trials Review, H2, 2013" report to their offering. Anal Fissure Global Clinical Trials Review, H2, 2013" provides data on the Anal Fissure clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anal Fissure. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anal Fissure. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Anal Fissure Therapeutics Clinical Trials - S.L.A. Pharma AG - Ventrus Biosciences, Inc. - Troikaa Pharmaceuticals Ltd. - SOFAR SPA - Ipsen S.A. - Dizney Display Company - Aptalis Pharma Inc. - Allergan, Inc. - Abbott Laboratories Clinical Trial Overview of Top Institutes / Government - Bushehr University of Medical Sciences - Birjand University of Medical Sciences - Institute of Child and Mother Health - Mazandaran University of Medical Sciences - SB Istanbul Education and Research Hospital - Rikshospitalet University Hospital - Ankara University - Huazhong University of Science & Technology - Universita degli Studi di Palermo - Hospital Universitario Reina Sofia For more information visit http://www.researchandmarkets.com/research/ww...al_fissure
Pipeline Progress at Ventrus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 29, 3:00PM CST
Ventrus completed patient enrollment and randomization of a phase III study on VEN 307.
Ventrus Biosciences Inc concludes enrolment in the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream in anal fissure patients
M2 - Tue Nov 26, 6:42AM CST
Pharmaceutical company Ventrus Biosciences Inc (NasdaqCM:VTUS) reported on Monday the completion of patient admission in the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related to anal fissure (AF), a tear in the lining of the anal canal characterised by severe anal pain associated with or after bowel movements.
Ventrus Biosciences Completes Enrollment of Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients With Anal Fissure
GlobeNewswire - Mon Nov 25, 6:30AM CST
Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced that it has completed patient enrollment and randomization in the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related to anal fissure (AF). Ventrus anticipates that data from this Phase 3 study will be available in the first quarter of 2014, and it expects to file a New Drug Application (NDA) for VEN 307 in the second quarter of 2014.
Positive Results on Ventrus' Candidate, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 12, 3:10PM CDT
Ventrus announced positive results from its two clinical dermal safety studies and one pharmacokinetic study on VEN 307.
Ventrus climbs on anal fissure drug studies
AP - Wed Sep 11, 10:46AM CDT
NEW YORK (AP) — Shares of Ventrus Biosciences jumped Wednesday after the company reported positive clinical trial results for a drug designed to treat anal fissure.
SmallCapReview.com - Small Caps On The Move - VTUS, HNR
M2 - Wed Sep 11, 10:15AM CDT
Ventrus Biosciences (Nasdaq: VTUS). Trading at $3.49, Up $0.91. Today announced positive results from two clinical dermal safety studies and one pharmacokinetic (PK) study of diltiazem hydrochloride 2% cream (VEN 307). All three studies were conducted to support the Company's planned New Drug Application (NDA) for VEN 307 as a treatment for anal fissures (AF).
Ventrus Biosciences Announces Positive Results From Clinical Dermal Safety and Pharmacokinetic Studies of Diltiazem (VEN 307)
GlobeNewswire - Wed Sep 11, 7:00AM CDT
Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced positive results from two clinical dermal safety studies and one pharmacokinetic (PK) study of diltiazem hydrochloride 2% cream (VEN 307). All three studies were conducted to support the Company's planned New Drug Application (NDA) for VEN 307 as a treatment for anal fissures (AF).
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Ventrus Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadline -- VTUS
GlobeNewswire - Sun Jul 07, 9:23AM CDT
Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Ventrus Biosciences, Inc. ("Ventrus" or the "Company"
(Nasdaq:VTUS) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 13 CIV 3429, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Ventrus between December 17, 2010 and July 25, 2012, both dates inclusive (the "Class Period" . This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Ventrus Biosciences, Inc. to Contact the Firm
GlobeNewswire - Wed Jul 03, 7:37PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of Ventrus Biosciences, Inc. ("Ventrus" or the "Company"
(Nasdaq:VTUS) of the Monday, July 8, 2013 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain executives. VENTRUS BIOSCIENCES ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Ventrus Biosciences, Inc. of Class Action Lawsuit and the Deadline of July 8, 2013 to Seek a Lead Plaintiff Position
PR Newswire - Tue Jul 02, 12:36PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Ventrus Biosciences, Inc. ("Ventrus" or the "Company"
(NasdaqCM: VTUS) stock between December 17, 2010 and June 25, 2012 (the "Class Period" . 
